Moorestown, NJ (September 23, 2019) – CareKinesis®, a subsidiary of Tabula Rasa HealthCare (NASDAQ:TRHC), hosted its 13th Clinical Advisory Panel (CAP) meeting September 19-20, 2019 in Lake Nona, Orlando, Florida. The annual meeting brought together Program of All-Inclusive Care for the Elderly (PACE) medical directors from across the country.
The CareKinesis meeting is a highly anticipated training and education event for PACE medical directors. CME, ACPE and CNE continuing education credits are available to attendees.
The first day was devoted to orienting new medical directors in pharmacodynamics and pharmacokinetics. The first session focused on medication risk specifically in older adults. Another focused on the milestones in competitive inhibition and drug research, importantly, how genetic variants affect multi-drug regimen pharmacokinetics and pharmcodynamics.
The next day’s agenda included topics focused on behavioral and psychological symptoms of dementia and antipsychotics; cost considerations of biologics; precision pharmacotherapy; and pharmacogenomics (PGx) of opioids and alternatives.
“The CareKinesis CAP meeting offers a productive forum for our clinical pharmacists, clinical researchers and technology product managers to interact with the medical directors, ensuring we are collaborating for the maximum benefit of our PACE participants,” said TRHC President Orsula V. Knowlton, PharmD, MBA.
The Panel received an update from TRHC Chairman, CEO and Founder Calvin H. Knowlton, PhD; toured TRHC’s newest location, the Precision Pharmacotherapy Research & Development Institute in Lake Nona; and heard guest speaker Alan Meeker, CEO of genomics-testing company CQuentia, speak on the topic of ‘Molecular Diagnostics Next Generation DNA Sequencing of Microbes: Moving to Precision Medicine.’
PACE is a federal program that provides comprehensive medical and social services to individuals 55 and older who are nursing-home eligible. There are 130 PACE programs operating 260 PACE centers in 31 states and serving more than 51,000 participants. The goal of PACE is to keep participants living in their own communities by providing comprehensive medical and social services.
TRHC provides technology, services, and consulting to approximately 80% of PACE programs nationwide to optimize participant outcomes and assure regulatory compliance. The Company’s medication safety and pharmacy services feature proprietary Medication Risk Mitigation software. CareKinesis pharmacists are board-certified in geriatrics leading to improved medication outcomes, increased adherence, and reduced participant hospitalizations.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize performance to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications, including EireneRx® and MedWise™, provide solutions for a range of payers, providers and other healthcare organizations. For more information please visit, www.tabularasahealthcare.com.
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 1, 2019, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website http://ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.
Bob East or Asher Dewhurst
T: (443) 213-0500